Lipopolysaccharide upregulates renal Shiga toxin receptors in a primate model of hemolytic uremic syndrome

American Journal of Nephrology

Volumn 25, Issue 6, 2005, Pages 536-540

  Clayton, Frederic ^a   Pysher, Theodore J ^a   Lou, Randall ^a   Kohan, Donald E ^a   Denkers, Nathaniel D ^a   Tesh, Vernon L ^b   Taylor Jr , Fletcher B ^c   Siegler, Richard L ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Hemolytic uremic syndrome; Lipopolysaccharide; Renal Shiga toxin receptors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GLOBOTRIAOSYLCERAMIDE; RECEPTOR; SHIGA TOXIN RECEPTOR; UNCLASSIFIED DRUG; VEROTOXIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BABOON; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEMOLYTIC UREMIC SYNDROME; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; LIPID ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THIN LAYER CHROMATOGRAPHY;

ANIMALS; CHROMATOGRAPHY, THIN LAYER; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; KIDNEY CORTEX; LIPOPOLYSACCHARIDES; MICROSCOPY, FLUORESCENCE; SHIGA-LIKE TOXIN I; TRIHEXOSYLCERAMIDES; UP-REGULATION;

EID: 29144451448     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088523     Document Type: Article

References (25)

1. Siegler RL: The hemolytic uremic syndrome. Pediatr Clin North Am 1995;42:1505-1529.
2. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O'Brien AD, Samuel JE: Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 1993;61:3392-3402.
3. Pai CH, Kelly JK, Meyers GL: Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. Infect Immun 1986;51:16-23.
4. Taylor FB Jr, Tesh VL, DeBault L, Li A, Chang AC, Kosanke SD, Pysher TJ, Siegler RL: Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. Am J Pathol 1999;154:1285-1299.
5. Siegler RL, Pysher TJ, Tesh VL, Taylor FB Jr: Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 2001;12:1458-1467.
6. Siegler RL, Pysher TJ, Lou R, Tesh VL, Taylor FB Jr: Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome. Am J Nephrol 2001;21:420-425.
7. Koster F, Levin J, Walker L, Tung KS, Gilman RH, Rahaman MM, Majid MA, Islam S, Williams RC Jr: Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med 1978;298:927-933.
8. Coratelli P, Buongiorno E, Passavanti G: Endotoxemia in hemolytic uremic syndrome. Nephron 1988;50:365-367.
9. Bitzan M, Moebius E, Ludwig K, Muller-Wiefel DE, Heesemann J, Karch H: High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome. J Pediatr 1991;119:380-385.
10. Heyderman RS, Fitzpatrick MM, Barclay GR: Haemolytic-uraemic syndrome. Lancet 1994;343:1042.
11. Kita E, Yunou Y, Kurioka T, Harada H, Yoshikawa S, Mikasa K, Higashi N: Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 2000;68:1207-1214.
12. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484-15488.
13. van Setten PA, van Hinsbergh VW, van der Velden TJ, van de Kar NC, Vermeer M, Mahan JD, Assmann KJ, van den Heuvel LP, Monnens LA: Effects of TNF alpha on verotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1996;51:1245-1256.
14. Stricklett PK, Hughes AK, Ergonul Z, Kohan DE: Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J Infect Dis 2002;186:976-982.
15. Tesh VL, Ramegowda B, Samuel JE: Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun 1994;62:5085-5094.
16. Ergonal Z, Clayton F, Fogo AB, Kohan DE: Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol 2003;18:246-253.
17. Hughes AK, Stricklett PK, Kohan DE: Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 1998;54:426-437.
18. Inward CD, Howie AJ, Fitzpatrick MM, Rafaat F, Milford DV, Taylor CM: Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol 1997;11:556-559.
19. Uchida H, Kiyokawa N, Horie H, Fujimoto J, Takeda T: The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Pediatr Res 1999;45:133-137.
20. Siegler RL, Edwin SS, Christofferson RD, Mitchell MD: Plasma and urinary cytokines in the childhood hemolytic uremic syndrome (HUS) (abstract). J Am Soc Nephrol 1991;2:274.
21. Karpman D, Andreasson A, Thysell H, Kaplan BS, Svanborg C: Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995;9:694-699.
22. Walker R, Fletcher J: Evidence that Injury to Platelets Can Contribute to the Diversity of Host Responses to Endotoxin. Amsterdam, Elsevier, Biomedical Press, 1980.
23. Roth RI: Hemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin. Blood 1994;83:2860-2865.
24. Palermo M, Alves-Rosa F, Rubel C, Fernandez GC, Fernandez-Alonso G, Alberto F, Rivas M, Isturiz M: Pretreatment of mice with lipopolysaccharide (LPS) or IL-1β exerts dose-dependent opposite effects on Shiga toxin-2 lethality. Clin Exp Immunol 2000;119:77-83.
25. Barrett TJ, Potter ME, Wachsmuth IK: Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice. Infect Immun 1989;57:3434-3437.